2.86

0.35% 0.010

After Hours: 2.86

Anavex Life Sciences Corp (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corp stock is traded at $2.86, with a volume of 307.11K. It is up +0.35% in the last 24 hours and down -9.21% over the past month. Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Previous Close:

$2.85

Open:

$2.82

24h Volume:

307.11K

Relative Volume:

0.28

Market Cap:

$265.11M

Revenue:

Net Income/Loss:

$-39.95M

P/E Ratio:

-6.1519

EPS:

-0.4649

Net Cash Flow:

$-34.08M

1W Performance:

-4.35%

1M Performance:

-9.21%

6M Performance:

-42.80%

1Y Performance:

-69.44%

1-Day Range:

$2.81

$2.905

1-Week Range:

$2.755

$2.9784

52-Week Range:

$2.255

$10.40

Anavex Life Sciences Corp Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corp

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2026-08-25

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL Anavex Life Sciences Corp	2.86	290.14M	0	-39.95M	-34.08M	-0.4649
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Anavex Life Sciences Corp Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corp Stock (AVXL) Latest News

Sep 04, 2026

PVG Asset Management targets Anavex (NASDAQ: AVXL) board in 2026 vote push - Stock Titan

Sep 03, 2026

Sep 02, 2026

Anavex Life Sciences Regains Nasdaq Compliance After Filing Quarterly Reports - marketscreener.com

Sep 02, 2026

Anavex Life Sciences regains Nasdaq compliance By Investing.com - Investing.com Nigeria

Sep 02, 2026

Anavex Life Sciences regains Nasdaq compliance after filing delayed 10-Qs - TradingView

Sep 02, 2026

Anavex Life Sciences regains Nasdaq compliance - Investing.com India

Sep 02, 2026

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement - Anavex Life Sciences

Sep 02, 2026

Anavex will keep trading on Nasdaq after filing its outstanding reports - Stock Titan

Sep 02, 2026

AVXL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Sep 02, 2026

New proxy contest hits Anavex (AVXL) as PVG presses its case for the 2026 shareholder vote - Stock Titan

Sep 02, 2026

Sep 01, 2026

PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual Meeting - The Manila Times

Sep 01, 2026

PVG Asset Management Corporation Files Definitive Proxy - GlobeNewswire

Sep 01, 2026

Aug 28, 2026

Anavex Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com

Aug 28, 2026

Anavex (AVXL) admits control weakness yet keeps Dec. 2025 numbers - Stock Titan

Aug 28, 2026

Aug 26, 2026

Anavex: After The EU Said No, The FDA Path Looks Long And Expensive - Seeking Alpha

Aug 26, 2026

Aug 25, 2026

Anavex Life Sciences Releases Q3 2026 Financial Results - AlphaStreet

Aug 25, 2026

Anavex Life Sciences reports Q3 FY2026 net income $7.8M, cash $118.3M - TradingView

Aug 25, 2026

Anavex Life Sciences: Fiscal Q3 Earnings Snapshot - KING5.com

Aug 25, 2026

Anavex Life Sciences (AVXL) Sees Stock Surge Following Q3 Update and Regulatory Progress - GuruFocus

Aug 25, 2026

Aug 20, 2026

Anavex (AVXL) Momentum: Moves 7.67% Down to $3.13; Technical Setup: the $2.97 to $3.29 Range Remains in Focus on the DayRetail Volume - Vinanet

Aug 20, 2026

PVG mounts six-seat board challenge at Anavex (AVXL) - Stock Titan

Aug 20, 2026